TORONTO, Jan. 10, 2013 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) today refiled its financial statements for the year ended September 30, 2012 to correct two oversights in the Consolidated Statements of Comprehensive Loss.
The previously filed Consolidated Statements of Comprehensive Loss had properly reported total revenue, total expenses, and net loss per share. However, the cost of goods sold reported for Virology products and technologies was misstated and should have read $3,807,360 rather than $2,502,288 for the year ending September 30, 2012, and $2,795,310 rather than $1,298,672 for the year ending September 30, 2011. Also, the International Financial Reporting Standards adjustments for the year ended September 30, 2011 was misstated as $5,391,611 and should have read $5,598,445. All other information contained in the previously filed financial statements for the year ended September 30, 2012 remains unchanged.
The refilled annual financial statements are available at www.SEDAR.com.
The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.
About Microbix Biosystems Inc.
Microbix Biosystems Inc. specializes in the development of the most advanced vaccine production technology and markets virology and biological products worldwide. In addition, The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Microbix supplies customers in the U.S., Europe, and Asia. Established in 1988, Microbix is headquartered in Toronto.
SOURCE: Microbix Biosystems Inc.
For further information:
Visit www.microbix.com or contact: Vaughn Embro-Pantalony, CEO, (416) 234-1624 x 350; or James Long, CFO, (416) 234-1624 x 265.